Cargando…

Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation

Atherosclerotic lesions are asymmetric focal thickenings of the intima of arteries that consist of lipids, various cell types and extracellular matrix (ECM). These lesions lead to vascular occlusion representing the most common cause of death in the Western world. The main cause of vascular occlusio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohwedder, Ina, Montanez, Eloi, Beckmann, Karsten, Bengtsson, Eva, Dunér, Pontus, Nilsson, Jan, Soehnlein, Oliver, Fässler, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407945/
https://www.ncbi.nlm.nih.gov/pubmed/22514136
http://dx.doi.org/10.1002/emmm.201200237
_version_ 1782239413068103680
author Rohwedder, Ina
Montanez, Eloi
Beckmann, Karsten
Bengtsson, Eva
Dunér, Pontus
Nilsson, Jan
Soehnlein, Oliver
Fässler, Reinhard
author_facet Rohwedder, Ina
Montanez, Eloi
Beckmann, Karsten
Bengtsson, Eva
Dunér, Pontus
Nilsson, Jan
Soehnlein, Oliver
Fässler, Reinhard
author_sort Rohwedder, Ina
collection PubMed
description Atherosclerotic lesions are asymmetric focal thickenings of the intima of arteries that consist of lipids, various cell types and extracellular matrix (ECM). These lesions lead to vascular occlusion representing the most common cause of death in the Western world. The main cause of vascular occlusion is rupture of atheromatous lesions followed by thrombus formation. Fibronectin (FN) is one of the earliest ECM proteins deposited at atherosclerosis-prone sites and was suggested to promote atherosclerotic lesion formation. Here, we report that atherosclerosis-prone apolipoprotein E-null mice lacking hepatocyte-derived plasma FN (pFN) fed with a pro-atherogenic diet display dramatically reduced FN depositions at atherosclerosis-prone areas, which results in significantly smaller and fewer atherosclerotic plaques. However, the atherosclerotic lesions from pFN-deficient mice lacked vascular smooth muscle cells and failed to develop a fibrous cap. Thus, our results demonstrate that while FN worsens the course of atherosclerosis by increasing the atherogenic plaque area, it promotes the formation of the protective fibrous cap, which in humans prevents plaques rupture and vascular occlusion.
format Online
Article
Text
id pubmed-3407945
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher WILEY-VCH Verlag
record_format MEDLINE/PubMed
spelling pubmed-34079452012-09-17 Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation Rohwedder, Ina Montanez, Eloi Beckmann, Karsten Bengtsson, Eva Dunér, Pontus Nilsson, Jan Soehnlein, Oliver Fässler, Reinhard EMBO Mol Med Research Articles Atherosclerotic lesions are asymmetric focal thickenings of the intima of arteries that consist of lipids, various cell types and extracellular matrix (ECM). These lesions lead to vascular occlusion representing the most common cause of death in the Western world. The main cause of vascular occlusion is rupture of atheromatous lesions followed by thrombus formation. Fibronectin (FN) is one of the earliest ECM proteins deposited at atherosclerosis-prone sites and was suggested to promote atherosclerotic lesion formation. Here, we report that atherosclerosis-prone apolipoprotein E-null mice lacking hepatocyte-derived plasma FN (pFN) fed with a pro-atherogenic diet display dramatically reduced FN depositions at atherosclerosis-prone areas, which results in significantly smaller and fewer atherosclerotic plaques. However, the atherosclerotic lesions from pFN-deficient mice lacked vascular smooth muscle cells and failed to develop a fibrous cap. Thus, our results demonstrate that while FN worsens the course of atherosclerosis by increasing the atherogenic plaque area, it promotes the formation of the protective fibrous cap, which in humans prevents plaques rupture and vascular occlusion. WILEY-VCH Verlag 2012-07 2012-04-19 /pmc/articles/PMC3407945/ /pubmed/22514136 http://dx.doi.org/10.1002/emmm.201200237 Text en Copyright © 2012 EMBO Molecular Medicine
spellingShingle Research Articles
Rohwedder, Ina
Montanez, Eloi
Beckmann, Karsten
Bengtsson, Eva
Dunér, Pontus
Nilsson, Jan
Soehnlein, Oliver
Fässler, Reinhard
Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title_full Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title_fullStr Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title_full_unstemmed Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title_short Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
title_sort plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407945/
https://www.ncbi.nlm.nih.gov/pubmed/22514136
http://dx.doi.org/10.1002/emmm.201200237
work_keys_str_mv AT rohwedderina plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT montanezeloi plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT beckmannkarsten plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT bengtssoneva plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT dunerpontus plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT nilssonjan plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT soehnleinoliver plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation
AT fasslerreinhard plasmafibronectindeficiencyimpedesatherosclerosisprogressionandfibrouscapformation